About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
- 2014 Rate Card & Production Specs
- 2013 Rate Card & Production Specs
- Advertising Due Dates
- BPA Statement
Statement of Purpose
Guidelines for Authors
Dr. Goldenberg reviews letrozole (Femara) for early breast cancer, lenalidomide (Revlimid) for anemia, and abatacept (Orencia) for rheumatoid arthritis.
Marvin M. Goldenberg, PhD, RPh, MS
Doctors need help in assisting their patients to understand the new Part D rules. Patients need help to avoid being “scammed.” Dr. Stefanacci helps us sort it out.
Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD
The authors discuss the appropriate indications of PPIs and focus on the negative ramifications of the widespread and long-term use of these agents.
Co Q. D. Pham, BSC, BA, BScPharm, PharmD, Linda M. Sadowski-Hayes, PharmD, and Randolph E. Regal, BS, PharmD
Topics covered include therapies for multiple myeloma, leukemia, sickle cell disease, and lymphoma.
Reuben B. David
The authors report on advances in the treatment of maxillary sinusitis, otitis media, skin and skin structure infections, diarrhea, gram-negative bacterial infections, zygomycosis, infectious mononucleosis, and combination therapy for HIV infection
Lawrence M. Prescott, PhD, and Sharon L. Prescott
The essays in “Ethics and the Pharmaceutical Industry” address the complex inter relationships between drug companies, clinicians, patients, and advocacy groups.
Alan Kaell, MD
David Nash, MD, MBA discusses the virtues of bar-coded medication administration, a powerful technology developed to prevent medical errors.
David Nash, MD, MBA
Matthew Grissinger, RPh, FASCP, presents Part 2 of a survey on frequent and fatal errors in the workplace and the effects of warnings and sanctions on the rate of errors.
Matthew Grissinger, RPh, FASCP
Stephen Barlas discusses the differences of opinion about the FDAâ€™s new rule regarding changes to drug package inserts, which are intended to clarify information for physicians and patients.
The authors review sildenafil citrate (Revatio) for the treatment of pulmonary arterial hypertension.
Amber Bell, PharmD Candidate, Myesha Davis, PharmD Candidate, Fran Close, PhD, Marlon Honeywell, PharmD, and Evans Branch III, PharmD